Allogene Therapeutics develops allogeneic chimeric antigen receptor T cell, or AlloCAR T, product candidates for cancer and autoimmune disease. The clinical-stage biotechnology company focuses on off-the-shelf CAR T approaches, including cemacabtagene ansegedleucel, or cema-cel, in large B-cell lymphoma and ALLO-329, a dual CD19/CD70 CAR T candidate for autoimmune diseases.
Recurring news covers clinical and regulatory updates for Allogene's studies, scientific presentations and publications, platform technologies such as Dagger®, and data related to MRD-guided treatment approaches. Company updates also include quarterly financial results, business updates, shareholder matters, and common stock financing activity tied to research, development, clinical trials, and corporate operations.
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology firm, announced its participation in seven investor conferences throughout April to June 2022. Key events include the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14, BofA Securities Healthcare Conference on May 10, and the Stifel Virtual Cell Therapy Conference on June 30. Webcasts for these events will be available on their website, with replays accessible for 30 days. Allogene focuses on developing allogeneic CAR T products aiming to provide effective cancer treatments to patients.
Allogene Therapeutics (Nasdaq: ALLO) has released promising preclinical data demonstrating that anti-BCMA CAR T cells from healthy donors exhibit superior immune fitness and cancer-killing activity compared to those derived from multiple myeloma patients. The research, published in Cancer Research Communications, indicates that these allogeneic CAR T cells have higher counts, better CD4/CD8 ratios, and effective cytotoxicity against multiple myeloma. Allogene's ongoing Phase 1 trials for ALLO-715 and ALLO-605 aim to further evaluate these promising therapies, with a clinical update expected by the end of 2022.
Allogene Therapeutics (Nasdaq: ALLO) announced FDA has granted Fast Track designation to ALLO-316, its first AlloCAR T therapy targeting CD70 for advanced clear cell renal cell carcinoma (RCC). This designation underscores ALLO-316's potential to address the unmet needs of patients resistant to standard RCC treatments, with a five-year survival rate of under 15%. The ongoing Phase 1 TRAVERSE trial aims to evaluate ALLO-316's safety and efficacy.
ALLO-316's selectivity for CD70 may offer advantages in treating both solid tumors and hematologic malignancies.
Summary not available.
Allogene Therapeutics (ALLO) announced the resumption of its AlloCAR T clinical studies following the lifting of a clinical hold by the FDA in January 2022. The company has initiated patient enrollment for multiple trials, including the pivotal Phase 2 ALPHA2 trial for ALLO-501A targeting relapsed/refractory large B cell lymphoma. With $810 million available at the end of 2021, and a reported net loss of $257 million, Allogene anticipates 2022 operating expenses between $360 million and $390 million. Future updates are expected during a conference call scheduled today.
Allogene Therapeutics (Nasdaq: ALLO) will announce its fourth quarter and year-end 2021 financial results on February 23, 2022, after market close. A live audio webcast and conference call are scheduled for 2:00 PM PT/5:00 PM ET. The announcement highlights Allogene's work in developing allogeneic CAR T cell therapies, aiming for reliable, scalable treatments for cancer. The company emphasizes its commitment to innovation in cell therapy.
Allogene Therapeutics (Nasdaq: ALLO) has announced participation in four virtual investor conferences focused on oncology. These include the B. Riley Virtual Oncology Investor Conference on January 27, 2022, the 4th Annual Guggenheim Oncology Day on February 9, 2022, the Cowen 42nd Annual Health Care Conference on March 7, 2022, and the Oppenheimer's 32nd Annual Healthcare Conference on March 15, 2022. Webcasts will be available on the company's website, allowing for replays for approximately 30 days.
Allogene Therapeutics (Nasdaq: ALLO) has entered an exclusive global collaboration with Antion Biosciences to utilize Antion's miCAR technology for advancing allogeneic CAR T (AlloCAR T™) therapy. This partnership aims to enhance multiplex gene silencing capabilities, with potential applications in immune evasion strategies. Allogene will provide an upfront cash payment and a preferred equity investment, alongside developmental and commercial milestone payments, and single-digit royalties on product sales. The collaboration seeks to accelerate Allogene's research in cell therapies designed to treat cancer.
Allogene Therapeutics announced the removal of a clinical hold by the FDA on its AlloCAR T clinical trials following an investigation. The investigation confirmed the chromosomal abnormality found in a patient was unrelated to Allogene's manufacturing process or TALEN gene editing. Clinical trials across the AlloCAR T platform are set to resume, with the pivotal Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma expected to start in mid-2022, pending FDA discussions. The company expresses gratitude for the collaboration with the FDA and clinical investigators.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that its President and CEO, David Chang, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 12:45 p.m. PT. This presentation focuses on the development of allogeneic CAR T therapies for cancer by Allogene, a pioneering biotechnology firm based in South San Francisco. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event. For further details, visit www.allogene.com.